"As the first and only commercially available assay to measure integrase inhibitor resistance, PhenoSense Integrase exemplifies Monogram's leadership position in personalized medicine and the Company's continued commitment to develop innovative HIV diagnostics that tailor drug treatments to the individual patient," said Monogram CEO William Young. "As evidenced by today's product launch and last year's introduction of Trofile, Monogram is firmly committed to ensuring that cutting-edge diagnostics are readily available to meet the needs of patients and physicians."
The performance of the PhenoSense Integrase assay is validated in compliance with regulations specified by the Clinical Laboratories Improvement Amendments (CLIA) and is performed in Monogram's Clinical Reference Laboratory, which is accredited by the College of American Pathologists (CAP).
About PhenoSense Integrase Assay
PhenoSense Integrase determines the susceptibility of a patient's HIV-1
strain to integrase inhibitors. The region of the HIV genome that encodes
integrase is amplified from a patient blood sample and inserted into a
proprietary test vector that is used to generate virus particles that
replicate using the patient virus integrase protein. Completion of a single
replication cycle results in the production of luciferase activity in
infected cells. Infection in the presence of drug is performed
|SOURCE Monogram Biosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved